C-Stone : A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Bowel (colorectum),Head and neck,Lung,Sarcoma,Skin,Stomach and upper gastrointestinal tract,Urinary systemBladder,Colon,Colorectum,Cutaneous Squamous Cell Carcinoma (CSCC),Gastrointestinal stromal tumour (GIST),Gastro-oesophageal junction ,Head and neck,Liposarcoma,Lung,Merkel cell,Mesothelioma,Oesophagus,Rectum,Sarcoma,Small Cell Lung Cancer,Soft Tissue Sarcoma,Stomach

Trial Overview Read MoreRead more

This phase I trial is evaluating the safety and effectiveness of a new biological drug (CS1003) in patients with advanced cancers.
 

This trial is treating patients with advanced cancers (excluding blood cancers and cancers that have spread to the brain).

This is a systemic therapy trial .

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors

Commercial Sponsor

CStone Pharmaceuticals

Summary

This is a dose escalation and expansion study of CS1003. This trial is recruiting patients with: soft-tissue sarcoma, malignant pleural mesothelioma, bladder cancer, Merkel-cell carcinoma, gastro-intestinal stromal tumour (GIST), gastric cancers, oesophageal carcinoma, small cell lung cancer, large cell lung cancer, head and neck squamous cell carcinoma or cutaneous cell carcinoma, or any solid tumours with MSI-H or dMMR. Border Medical Oncology Research Unit is only participating in (expansion) Phase 1B of the study.

Recruiting Hospitals Read MoreRead more

Border Medical Oncology
Albury
Ms Nyree Sarakis
Nsarkis@bordermedonc.com.au
02 6064 1493

Monash Health, Medical Oncology
Clayton
Early Phase Research Study Coordinator
earlyphase.oncresearch@monashhealth.org
0474 769 510

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next